<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244333</url>
  </required_header>
  <id_info>
    <org_study_id>527.56</org_study_id>
    <nct_id>NCT02244333</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)</brief_title>
  <official_title>ALNA® - AWB in Pre-treated Patients With BPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment
      after switch from Terazosin-treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in International Prostatic Symptom Score (IPSS) by means on patient questionnaire</measure>
    <time_frame>Baseline, after 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Quality of Life (QoL) Index by means on patient questionnaire</measure>
    <time_frame>Baseline, after 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global comparative assessment of Terazosin and ALNA® treatment by investigator on a 3 point-scale</measure>
    <time_frame>after 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in maximum urinary flow rate (Qmax)</measure>
    <time_frame>Baseline, after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in residual urinary volume</measure>
    <time_frame>Baseline, after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in blood pressure</measure>
    <time_frame>Baseline, after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse rate (bpm)</measure>
    <time_frame>Baseline, after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in complications due to low blood pressure</measure>
    <time_frame>Baseline, after 1 month</time_frame>
    <description>Patient is asked for complications (weakness, dizziness, nausea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by investigator on 4-point scale</measure>
    <time_frame>after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by investigator on 4-point scale</measure>
    <time_frame>after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment with BPS- treatment by investigator on a 4-point scale</measure>
    <time_frame>Baseline, after 1 month</time_frame>
    <description>Switch from Terazosin therapy to ALNA®</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4575</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Patients with symptomatic BPS</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALNA®</intervention_name>
    <arm_group_label>Patients with symptomatic BPS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic BPS, who switched for ALNA® after preceding Terazosin therapy
        recruited at urologists
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suffering from BPS symptoms

          -  Preceding treating with Terazosin for at least one month

          -  IPSS sum score &gt;= 8 points prior to treatment start with ALNA® or complaints due to BP
             reduction by Terazosin

          -  Indication for a switch to treatment with ALNA® according to its Summary of Product
             Characteristics (SPC) for a minimum period of one month

        Exclusion Criteria:

          -  Patients fulfilling one of the general or specific contraindications listed in the
             ALNA® SPC, particularly patients with known hypersensitivities against tamsulosin
             hydrochloride or any other ingredients of the product, orthostatic dysregulation or
             severe liver insufficiency could not be included in the Post Marketing Surveillance
             (PMS) study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

